Dazodalibep Improves Systemic Sjögren Activity in Key Trial
Summary
The 1500-mg dose taken every 4 weeks generally outperforms the 3000-mg dose taken every 12 weeks compared with placebo.
Description from Medscape.
Who is covering this
-
Dazodalibep Improves Systemic Sjögren Activity in Key Trial
The 1500-mg dose taken every 4 weeks generally outperforms the 3000-mg dose taken every 12 weeks compared with placebo.
Comments
Comments need JavaScript.